• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Immatics N.V.

    7/22/24 4:05:27 PM ET
    $IMTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $IMTX alert in real time by email
    S-8 1 dp214868_s8.htm FORM S-8

     

    As filed with the Securities and Exchange Commission on July 22, 2024

     

    Registration No. 333-

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8

    REGISTRATION STATEMENT

    Under

    The Securities Act of 1933

     

    IMMATICS N.V.

    (Exact name of registrant as specified in its charter)

     

    The Netherlands Not Applicable

    (State or other jurisdiction of

    incorporation or organization)

    (I.R.S. Employer

    Identification Number)

     

    Paul-Ehrlich-Straße 15

    72076 Tübingen, Federal Republic of Germany

    Tel: +49 (7071) 5397-0

    (Address of Principal Executive Offices)

     

    Immatics N.V. 2024 Stock Option and Incentive Plan

    (Full Title of the Plans)

     

    Edward A. Sturchio

    Immatics US, Inc.

    2130 W. Holcombe Blvd., Suite 900

    Houston, Texas 77030

    (281) 810-7545

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

    Copies to:

     

    Yasin Keshvargar, Esq.

    Davis Polk & Wardwell LLP

    450 Lexington Avenue

    New York, NY 10017

    (212) 450-4000

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☐   Accelerated filer   ☒
    Non-accelerated filer   ☐   Smaller reporting company   ☐
            Emerging growth company   ☐


    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

    Part I

     

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

     

    The information specified in Item 1 and Item 2 of Part I of this Registration Statement on Form S-8 (this “Registration Statement”) is omitted from this filing in accordance with the provisions of Rule 428 under the Securities Act of 1933, as amended (the “Securities Act”) and the introductory note to Part I of the Registration Statement on Form S-8. The documents containing the information specified in Part I will be sent or given to participants as specified by Rule 428(b)(1) under the Securities Act.

     

    Part II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference.

     

    The registrant hereby incorporates by reference into this Registration Statement the following documents filed with the Securities and Exchange Commission (the “SEC”):

     

    (a)The registrant’s annual report on Form 20-F filed with the SEC on March 21, 2024 (File No. 001-39363) and the registrant’s reports on Form 6-K filed with the SEC on May 14, 2024 (File No. 001-39363) (only with respect to Exhibit 99.1 thereto);

     

    (b)All other reports filed pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), since the end of the fiscal year covered by the annual report; and

     

    (c)The description of the registrant’s ordinary shares contained in the registrant’s registration statement on Form 8-A (File No. 001-39363), filed by the registrant with the SEC under Section 12(b) of the Exchange Act, on July 1, 2020, including any amendments or reports filed for the purpose of updating such description.

     

    To the extent that any information contained in any report on Form 6-K, or any exhibit thereto, was furnished to, rather than filed with, the Commission, such information or exhibit is specifically not incorporated by reference.

     

    All documents that the registrant subsequently files pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act prior to the filing of a post-effective amendment to this Registration Statement which indicates that all of the ordinary shares offered have been sold or which deregisters all of such shares then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of the filing of such documents. Any report on Form 6-K furnished by the registrant to the Commission after the date of this Registration Statement (or a portion thereof) is incorporated by reference in this Registration Statement only to the extent that the report expressly states that the registrant incorporates it (or such portions) by reference in this Registration Statement and it is not subsequently superseded.

     

     

     

    Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

    Item 4. Description of Securities.

     

    Not applicable, see Item 3(c).

     

    Item 5. Interests of Named Experts and Counsel.

     

    Not applicable.

     

    Item 6. Indemnification of Directors and Officers.

     

    Under Dutch law, directors of a Dutch public company may be held jointly and severally liable to the company for damages in the event of improper performance of their duties. In addition, directors may be held liable to third parties for any actions that may give rise to a tort. This applies equally to our managing directors, supervisory directors, non-executive directors and executive directors.

     

    Pursuant to our articles of association and unless Dutch law provides otherwise, the following will be reimbursed to actual and former managing directors, supervisory directors, non-executive directors and executive directors and other members of the executive committee:

     

    (i)the costs of conducting a defense against claims, also including claims by the company and its group companies, as a consequence of any acts or omissions in the fulfillment of their duties or any other duties currently or previously performed by them at our request;

     

    (ii)any damages or financial penalties payable by them as a result of any such acts or omissions;

     

    (iii)any amounts payable by them under settlement agreements entered into by them in connection with any such acts or omissions;

     

    (iv)the costs of appearing in other legal proceedings in which they are involved in such capacity, with the exception of proceedings primarily aimed at pursuing a claim on their own behalf; and

     

    (v)any taxes payable by them as a result of any reimbursements.

     

    No indemnification shall be given to an indemnified officer or director under our articles of association unless:

     

    (i)it has been adjudicated by a Dutch court or, in the case of arbitration, an arbitrator, in a final and conclusive decision that the act or omission may be characterized as intentional, deliberately reckless or grossly negligent conduct, unless Dutch law provides otherwise or this would, in view of the circumstances of the case, be unacceptable according to standards of reasonableness and fairness; or

     

    (ii)the costs or financial loss are covered by an insurance and the insurer has paid out the costs or financial loss.

     

    We have entered into indemnification agreement with each of our directors and executive officers.

     

    Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers or persons controlling us pursuant to the foregoing provisions, we have been informed that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is theretofore unenforceable.

     

     

     

    Item 7. Exemption from Registration Claimed.

     

    Not applicable.

     

    Item 8. Exhibits.

     

    EXHIBIT INDEX

     

    Exhibit
    No.
      Description
       
    4.1   Deed of Conversion of Immatics B.V. and Articles of Association of Immatics N.V. (incorporated by reference to Exhibit 3.1 to the Registration Statement on Form F-1 (File No. 333-240260), filed with the SEC on July 31, 2020)
       
    4.2   Investor Rights and Lock-up Agreement (incorporated by reference to Exhibit 10.1 to the Registration Statement on Form F-1 (File No. 333-240260), filed with the SEC on July 31, 2020).
       
    5.1*   Opinion of NautaDutilh N.V.
       
    23.1*   Consent of PricewaterhouseCoopers GmbH Wirtschaftsprüfungsgesellschaft, Independent Registered Public Accounting Firm.
       
    23.2*   Consent of NautaDutilh N.V. (included in Exhibit 5.1).
       
    24.1*   Power of Attorney (included on signature page to this Registration Statement).
       
    99.1   2024 Stock Option and Incentive Plan (incorporated by reference to Exhibit 99.4 to the registrant’s reports on Form 6-K (File No. 001-39363), filed with the SEC on June 3, 2024).
         
    107.1*   Filing Fee Table.

     

    * Filed herewith.

     

    Item 9. Undertakings.

     

    (a)The registrant hereby undertakes:

     

    (1)To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

     

    (i)to include any prospectus required by Section 10(a)(3) of the Securities Act;

     

    (ii)to reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set

     

     

     

    forth in the “Calculation of Registration Fee” table in the effective registration statement; and

     

    (iii)to include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement;

     

    Provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) herein do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to Section 13 or Section 15(d) of the Exchange Act (15 U.S.C. 78m or 78o(d)) that are incorporated by reference in the Registration Statement.

     

    (2)That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (3)To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

     

    (b)The registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (c)Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Tübingen, Germany, on the 22 day of July, 2024.

     

      IMMATICS N.V.
         
      By:

    /s/ Harpreet Singh

        Harpreet Singh
        Chief Executive Officer and Director

     

     

    POWER OF ATTORNEY AND SIGNATURES

     

    KNOW ALL BY THESE PRESENT, that each individual whose signature appears below hereby constitutes and appoints Harpreet Singh and Arnd Christ, and each of them, either of whom may act without the joinder of the other, as his or her true and lawful attorneys-in-fact and agents with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8, and to file the same, with all exhibits thereto, and all documents in connection therewith, with the Securities and Exchange Commission granting unto each said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them, or his or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on the date indicated below.

     

    Name   Title   Date
             

    /s/ Harpreet Singh

    Harpreet Singh

     

    Chief Executive Officer and Director

    (Principal Executive Officer)

      July 22, 2024
             

    /s/ Arnd Christ

    Arnd Christ

     

    Chief Financial Officer

    (Principal Financial and Accounting Officer)

      July 22, 2024
             

    /s/ Peter Chambré

    Peter Chambré

      Chairman of the Board of Directors   July 22, 2024
             

    /s/ Michael G. Atieh

    Michael G. Atieh

      Director   July 22, 2024
             

    /s/ Paul R. Carter

    Paul R. Carter

      Director   July 22, 2024
             

    /s/ Eliot Forster

    Eliot Forster

      Director   July 22, 2024
             

    /s/ Mathias Hothum

    Mathias Hothum

     

    Director

     

      July 22, 2024
             

    /s/ Heather L. Mason

    Heather L. Mason

      Director   July 22, 2024
             

    /s/ Adam Stone

    Adam Stone

      Director   July 22, 2024
             

    /s/ Edward A. Sturchio

      US Authorized Representative   July 22, 2024

    Edward A. Sturchio

           

     

    Get the next $IMTX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IMTX

    DatePrice TargetRatingAnalyst
    9/18/2025$16.00Buy
    Guggenheim
    5/28/2025$10.00Buy
    Deutsche Bank
    10/7/2024$19.00Overweight
    Piper Sandler
    11/2/2023Overweight
    Cantor Fitzgerald
    3/31/2023$12.00Buy
    Mizuho
    3/24/2023$16.00Buy
    Bryan Garnier
    7/15/2021$26.00 → $27.00Outperform
    SVB Leerink
    More analyst ratings

    $IMTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Guggenheim initiated coverage on Immatics N.V. with a new price target

    Guggenheim initiated coverage of Immatics N.V. with a rating of Buy and set a new price target of $16.00

    9/18/25 8:43:36 AM ET
    $IMTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Deutsche Bank initiated coverage on Immatics N.V. with a new price target

    Deutsche Bank initiated coverage of Immatics N.V. with a rating of Buy and set a new price target of $10.00

    5/28/25 9:08:28 AM ET
    $IMTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Piper Sandler initiated coverage on Immatics N.V. with a new price target

    Piper Sandler initiated coverage of Immatics N.V. with a rating of Overweight and set a new price target of $19.00

    10/7/24 7:57:11 AM ET
    $IMTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IMTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Immatics Presents IMA203CD8 PRAME Cell Therapy Data from Ongoing Dose Escalation and Shows Promising Initial Anti-tumor Activity in PRAME-Positive Tumors at ESMO-IO 2025 Congress

    IMA203CD8 is a second-generation PRAME cell therapy with enhanced pharmacology in ongoing Phase 1a dose escalationManageable tolerability across all dose levelsEncouraging early clinical anti-tumor activity in advanced solid tumors after one-time infusion of IMA203CD8 at a low median dose during ongoing dose escalation, including deep and durable responses Promising dose-dependent clinical signal in ovarian carcinoma supports the strategy to position IMA203CD8 in the tumor-agnostic setting of advanced PRAME cancers beyond melanoma, starting with gynecologic cancersDose escalation and determination of RP2D on track to be completed in 2026, including data on two highest dose levels Houston, T

    12/11/25 7:00:00 AM ET
    $IMTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Immatics Announces $125 Million Underwritten Offering

    Houston, Texas and Tuebingen, Germany, December 05, 2025 – Immatics N.V. (NASDAQ:IMTX, "Immatics" or the "Company")), a clinical-stage biopharmaceutical company and the global leader in precision targeting of PRAME, announced today that it has agreed to sell 12,500,000 ordinary shares at $10.00 per share in an underwritten offering. The gross proceeds from the offering, before deducting the underwriting discount and offering expenses, are expected to be $125 million. The offering is expected to close on December 8, 2025, subject to customary closing conditions.   Jefferies, Leerink Partners and Cantor are acting as joint book-running managers for the offering. A registration statement rela

    12/5/25 6:00:00 AM ET
    $IMTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Immatics Announces Third Quarter 2025 Financial Results and Business Update

    Anzu-cel (anzutresgene autoleucel, IMA203) PRAME Cell Therapy: Global, randomized, controlled Phase 3 trial, SUPRAME, in previously treated advanced melanoma ongoing; interim and final analyses will occur in 2026 Anzu-cel (IMA203) PRAME Cell Therapy: One-time infusion continues to show strong clinical benefit and favorable tolerability in 16 patients with metastatic uveal melanoma in latest update on Phase 1b data presented at the ESMO 2025 Presidential Symposium: cORR of 67%, mDOR of 11.0 months, mPFS of 8.5 months and mOS not reached at 14.3 months mFUIMA203CD8 PRAME Cell Therapy (GEN2): Phase 1a clinical trial ongoing with next data update, including dose escalation data in ovarian cancer

    11/17/25 7:00:00 AM ET
    $IMTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IMTX
    SEC Filings

    View All

    SEC Form 6-K filed by Immatics N.V.

    6-K - Immatics N.V. (0001809196) (Filer)

    1/12/26 4:09:23 PM ET
    $IMTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 6-K filed by Immatics N.V.

    6-K - Immatics N.V. (0001809196) (Filer)

    12/11/25 7:10:17 AM ET
    $IMTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 6-K filed by Immatics N.V.

    6-K - Immatics N.V. (0001809196) (Filer)

    12/8/25 4:20:54 PM ET
    $IMTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IMTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Immatics N.V.

    SC 13G - Immatics N.V. (0001809196) (Subject)

    11/14/24 1:28:33 PM ET
    $IMTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Immatics N.V.

    SC 13G - Immatics N.V. (0001809196) (Subject)

    11/14/24 6:32:45 AM ET
    $IMTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Immatics N.V.

    SC 13G/A - Immatics N.V. (0001809196) (Subject)

    11/8/24 10:46:38 AM ET
    $IMTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IMTX
    Leadership Updates

    Live Leadership Updates

    View All

    Immatics Announces Third Quarter 2025 Financial Results and Business Update

    Anzu-cel (anzutresgene autoleucel, IMA203) PRAME Cell Therapy: Global, randomized, controlled Phase 3 trial, SUPRAME, in previously treated advanced melanoma ongoing; interim and final analyses will occur in 2026 Anzu-cel (IMA203) PRAME Cell Therapy: One-time infusion continues to show strong clinical benefit and favorable tolerability in 16 patients with metastatic uveal melanoma in latest update on Phase 1b data presented at the ESMO 2025 Presidential Symposium: cORR of 67%, mDOR of 11.0 months, mPFS of 8.5 months and mOS not reached at 14.3 months mFUIMA203CD8 PRAME Cell Therapy (GEN2): Phase 1a clinical trial ongoing with next data update, including dose escalation data in ovarian cancer

    11/17/25 7:00:00 AM ET
    $IMTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Immatics Appoints Amie Krause as Chief People Officer

    Houston, Texas and Tuebingen, Germany, October 27, 2025 – Immatics N.V. (NASDAQ:IMTX, "Immatics" or the "Company")), a clinical-stage biopharmaceutical company and the global leader in precision targeting of PRAME, today announced the appointment of Amie Krause as Chief People Officer ("CPO") effective October 27, 2025. Ms. Krause brings more than 20 years of experience in shaping culture, leading organizational growth and aligning talent with business strategy, including across global biopharmaceutical companies. In this newly established role, she will lead Immatics' human resources, focusing on organizational development and operations as the company transitions to commercial stage."As we

    10/27/25 7:00:00 AM ET
    $IMTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Immatics Appoints Venkat Ramanan as Chief Financial Officer

    Houston, Texas and Tuebingen, Germany, October 1, 2025 – Immatics N.V. (NASDAQ:IMTX, "Immatics" or the "Company")), a clinical-stage biopharmaceutical company and the global leader in precision targeting of PRAME, today announced the appointment of Venkat Ramanan, Ph.D., as Chief Financial Officer ("CFO"), effective immediately. Dr. Ramanan is a seasoned financial leader in the biopharmaceutical industry with over 25 years of experience at companies including Seagen, Gilead Sciences and Amgen. He brings deep financial expertise in facilitating successful product launches, establishing scalable operations in global markets and enabling corporate transactions. He joins Immatics from Anthos The

    10/1/25 7:00:00 AM ET
    $IMTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IMTX
    Financials

    Live finance-specific insights

    View All

    Immatics Achieves Clinical Proof-of-Concept of its Next-Generation TCR Bispecific (TCER®) Pipeline with Data on IMA402 (PRAME) and IMA401 (MAGEA4/8) and Announces Next Development Steps

    Company to host conference call and webcast today, November 12, at 8:30 am EST/2:30 pm CET IMA402 and IMA401 TCR Bispecifics showed favorable tolerability at RP2D as well as deep and durable responses in heavily pre-treated, last-line patients with a range of solid tumors IMA402 PRAME Bispecific at RP2D range resulted in a 30% cORR (6/20) across all indications, including 29% (4/14) in melanoma and 2/3 confirmed responses in ovarian carcinoma IMA401 MAGEA4/8 Bispecific at ≥1 mg resulted in a 25% cORR (2/8) in head and neck cancer, 29% cORR (2/7) in melanoma and promising clinical activity in sqNSCLC Phase 1a dose escalation completed for both trials; data support IMA402 PRAME Bispecific dev

    11/12/25 7:00:00 AM ET
    $IMTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Immatics Announces Updated Phase 1b Clinical Data on ACTengine® IMA203 TCR-T Targeting PRAME in Melanoma Patients and Provides Update on Upcoming SUPRAME Phase 3 Trial

    Company to host conference call and webcast today, October 10, at 9:00 am EDT/3:00 pm CEST Company announces updated Phase 1b clinical data on ACTengine® IMA203 targeting PRAME in 28 heavily pretreated metastatic melanoma patients with substantially enhanced maturity compared to the last data update in May 2024 and provides the first report on progression-free survival (PFS) and overall survival (OS)Based on the Phase 1b data, the Company will proceed directly to a registration-enabling Phase 3 trial Regulatory pathway and clinical trial design for IMA203 finalized following FDA Type D meetings and meeting with the Paul Ehrlich Institute (PEI); RP2D and CMC package confirmedIMA203 conti

    10/10/24 6:30:00 AM ET
    $IMTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Immatics Reports Interim Clinical Data from ACTengine® IMA203 and IMA203CD8 TCR-T Monotherapies Targeting PRAME in an Ongoing Phase 1 Trial

    Company to host conference call and webcast today, November 8, at 8:30 am EST/2:30 pm CET IMA203 data with focus on melanoma patients presented at the International Congress of the Society for Melanoma Research today, November 8 IMA203 GEN1 TCR cell therapy targeting PRAME – update on Phase 1a and Cohort A Continues to be well tolerated50% confirmed objective response rate (cORR) in melanoma patients treated at recommended Phase 2 dose; durability with some ongoing responses at >15 months and median duration of response not reached at a median follow-up of 14.4 monthsTargeted to enter registration-enabling Phase 2 trial in melanoma in 2024; discussions with FDA ongoing based on recently ob

    11/8/23 7:00:00 AM ET
    $IMTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care